Reuters logo
BRIEF-PDS Biotechnology reports positive phase I results in proprietary HPV-cancer immunotherapy
May 28, 2015 / 11:14 AM / 2 years ago

BRIEF-PDS Biotechnology reports positive phase I results in proprietary HPV-cancer immunotherapy

May 28 (Reuters) - Netscientific Plc

* PDS Biotechnology reports positive Phase I results

* PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-cancer immunotherapy

* Results are first demonstration of PDS Biotechnology’s proprietary synthetic immunotherapy technology, Versamune’s , application in human cancer

* Showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong t-cell responses in pre-cervical cancer

* Now look forward to seeing phase II trials begin Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below